Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib for ALS
NCT05105958Phase 2Not yet recruiting
- Sponsor
- University of Zurich
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tideglusib in amyotrophic lateral sclerosis (ALS), sponsored by University of Zurich. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tideglusib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05105958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105958.